ResApp Health
(ASX:RAP) has received CE Mark approval for ResAppDx-EU version 2, the latest version of the world’s first smartphone-based diagnostic test for respiratory disease which now addresses both adults and children.
This CE Mark approval is an extension of the existing CE Mark approval - it adds the ability to test adults for lower respiratory tract disease, pneumonia, asthma and chronic obstructive pulmonary disease (COPD).
It means it meets the essential requirements of the European regulations and allows for its sale throughout the European Economic Area.
ResApp’s cough-based diagnostic algorithms have been shown in pivotal clinical studies to accurately diagnose the most common adult and paediatric acute respiratory diseases when compared with a panel of experienced clinicians.
Shares in ResApp Health
(ASX:RAP) closed 12.82 per cent higher at $0.22 yesterday.
